Back to Trial

Oracle Runs

Oracle findings and outcome history for Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma (NCT06102005).

Runs
4
Findings
4
Latest Run
Apr 6, 2026, 2:57 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial listed as completed (primary ~Feb 2026) on ClinicalTrials.gov and sponsor pages, but no public efficacy readout, results posting, or interpretation of the primary endpoint (exacerbation rate) found. Prior PoM data positive but for a different early study, not this exact Phase 2b dose-ranging trial. Evidence incomplete and not trial-specific.

Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM
ClinicalTrialsclinicaltrials.gov
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Completed; primary completion 2026-02-23. No results posted or efficacy data on annualized exacerbation rate.
Sponsorsanofi.comApr 15, 2025, 5:00 AM
Press Release: Sanofi's respiratory pipeline advances with new data in asthma...
Readout of AIRCULES phase 2 (NCT06102005) anticipated in 2026. No results or positive/negative framing provided.
NO_DECISIONDismissed80% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov lists this study as completed but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
ClinicalTrialsclinicaltrials.govMar 17, 2026, 12:00 AM
Study Details | NCT06102005 | ClinicalTrials.gov
ClinicalTrials.gov lists completed; primary completion 2026-02-23; hasResults=false on the latest posted update.
NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific efficacy readout was found. Sanofi materials continued to describe AIRCULES (NCT06102005) as an anticipated H1 2026 readout, and the study record shows completion around March 2026. Without a public result framed for this exact trial, positivity cannot be judged.

Found Apr 3, 2026, 4:08 PMReviewed Apr 3, 2026, 4:47 PM
Sponsorsanofi.comApr 15, 2025, 5:00 AM
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi said the AIRCULES phase 2 study (NCT06102005) in moderate-to-severe asthma was anticipated to read out in 2026; no results were disclosed for this trial.
Sponsorsanofi.comJan 29, 2026, 12:00 AM
Sanofi Q4/FY 2025 Results presentation
Sanofi's upcoming news flow still listed lunsekimig–asthma as an H1 2026 phase 2 data readout, indicating the result was still pending at that time.
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06102005 | Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
ClinicalTrials.gov lists NCT06102005 (AIRCULES) and shows completion around 2026-03-23, but no posted trial outcome was identified from the public record snippet.
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific efficacy readout was found. Sanofi’s April 2025 press release said AIRCULES (NCT06102005) readout was anticipated in 2026, and its December 2025 pipeline review still listed phase 2 readout in H1 2026. That supports no public positive/negative readout yet for this exact Phase 2 trial.

Found Apr 1, 2026, 7:12 PMReviewed Apr 1, 2026, 7:16 PM
Sponsorsanofi.comApr 15, 2025, 5:00 AM
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi states the AIRCULES phase 2 study (NCT06102005) in moderate-to-severe asthma has readout anticipated in 2026, indicating no public efficacy outcome yet at that time.
Sponsorsanofi.comDec 16, 2025, 12:00 AM
Sanofi Year-end late-stage pipeline review presentation
The pipeline slide for lunsekimig lists AIRCULES (NCT06102005) with 'Phase 2 study readout in H1 2026,' again showing no disclosed positive or negative trial readout by Dec. 2025.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.